Cargando…
Thrombotic microangiopathy during carfilzomib use: case series in Singapore
Autores principales: | Chen, Y, Ooi, M, Lim, S F, Lin, A, Lee, J, Nagarajan, C, Phipps, C, Lee, Y S, Grigoropoulos, N F, Lao, Z, Surendran, S, Teh, E M, Goh, Y T, Chng, W J, Gopalakrishnan, S K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030383/ https://www.ncbi.nlm.nih.gov/pubmed/27471866 http://dx.doi.org/10.1038/bcj.2016.62 |
Ejemplares similares
-
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
por: Eigbire-Molen, Odianosen, et al.
Publicado: (2022) -
Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
por: Gosain, Rahul, et al.
Publicado: (2017) -
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
por: Chen, Yunxin, et al.
Publicado: (2021) -
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
por: Hobeika, Liliane, et al.
Publicado: (2014) -
Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)